Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cannabis Use and Neural Glutamate Homeostasis
NCT05664763Phase 1Terminated
- Sponsor
- Yale University
- Start
- Mar 2023
- Primary completion
- Jul 2024
- Countries
- 1
01
Overview
Phase 1, open-label trial in cannabis use disorder (CUD) (2 arms), sponsored by Yale University. Primary endpoint: Metabotropic Glutamate Receptor 5 Availability at Day 28. Started Mar 2023; status: terminated.
02
Conditions
cannabis use disorder (CUD)
Beyond the preview
Go deeper on NCT05664763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05664763.